Meeting
2023 ASCO Annual Meeting
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.
Authors
Charlotte Andrieu
National Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Dublin, Ireland
Charlotte Andrieu , Dalal Al-Sultan , Laura Ivers , Jose Javier Berenguer Pina , Darko Skrobo , Josephine Ballot , Alex J. Eustace , Cecily Quinn , Giuseppe Gullo , Naomi Walsh , John Crown
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1016)
DOI
10.1200/JCO.2023.41.16_suppl.1016
Abstract #
1016
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Decreased copy number aberrations in genomes of HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary durable complete responses (dCR) to trastuzumab (T).
First Author: Alanna Maguire
Poster
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
First Author: Mark Danese
Poster
2012 Breast Cancer Symposium
Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC).
First Author: Denise Yardley
Poster
2012 ASCO Annual Meeting
Long-term follow-up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and trastuzumab (T) for HER2-altered (HER2+) metastatic breast cancer (MBC).
First Author: Giuseppe Gullo